journal
MENU ▼
Read by QxMD icon Read
search

Melanoma Research

journal
https://www.readbyqxmd.com/read/28727675/type-1-diabetes-mellitus-caused-by-treatment-with-low-dose-interferon-%C3%AE-in-a-melanoma-patient
#1
Daniel Sossau, Lukas Kofler, Thomas Eigentler
Interferon-α (INF-α) is used as an adjuvant treatment for high-risk cutaneous melanoma. It has a large variety of potentially severe and irreversible side effects and can contribute toward the development of autoimmune disease. We report a case of a 59-year-old woman who developed type 1 diabetes following the use of low-dose IFN-α for the adjuvant treatment of stage IIB melanoma. Fifteen months after initiating IFN-α, she presented with blood glucose of 1126 mg/dl, hyponatremia, and microalbuminuria...
July 19, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28723726/impact-of-socioeconomic-status-and-district-of-residence-on-cutaneous-malignant-melanoma-prognosis-a-survival-study-on-incident-cases-between-1991-and-2011-in-the-province-of-ferrara-northern-italy
#2
Alessandro Borghi, Monica Corazza, Annarosa Virgili, Anna G Lambertini, Nicola Caranci, Barbara Pacelli, Paolo Carcoforo, Stefano Ferretti
The aim of this study was to analyse the impact of socioeconomic status (SES) on the prognosis of patients with invasive malignant melanoma (MM) incident from 1991 to 2011 in the province of Ferrara, northern Italy. A total of 750 patients provided by the Area Vasta Emilia Centrale Cancer Registry were included in this retrospective cohort study. Prognosis was analysed in terms of overall survival and specific survival. The study determinants were the patients' SES and district of residence. The confounding effect of sex, age, period and TNM stage at diagnosis was evaluated...
July 18, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28723725/meningeal-melanomatosis-following-discontinuation-of-dabrafenib-implications-for-the-maintenance-of-long-term-complete-remission
#3
Victoria Grätz, Nadine Lüttmann, Ozan Haase, Ewan A Langan, André Kemmling, Detlef Zillikens, Patrick Terheyden
A subset of 10-20% of patients under continuous BRAF inhibitor monotherapy achieve long-term progression-free and overall survival. Definitive criteria for the safe cessation of BRAF inhibitor monotherapy in treatment-responsive melanoma patients are lacking. We report a patient who remained in complete remission (CR) for 5 years under dabrafenib. The treatment was withdrawn because of concerns about cardiac toxicity. Four months thereafter the patient developed neurological symptoms, including diplopia and bilateral visual loss...
July 18, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28692456/focal-necrotizing-myopathy-with-dropped-head-syndrome-induced-by-cobimetinib-in-metastatic-melanoma
#4
Marie-Léa Gauci, Pauline Laly, Leonard-Louis Sarah, Anthony Behin, Jérémy Gottlieb, Isabelle Madelaine-Chambrin, Barouyr Baroudjian, Laetitia Da-Meda, Samia Mourah, Maxime Battistella, Nicole Basset Seguin, Martine Bagot, Cécile Pages, Laetitia Vercellino, Thierry Maisonobe, Céleste Lebbé
Therapeutic advances derived from targeted therapy and immune checkpoint inhibitors can improve melanoma prognosis. Since 2015, cobimetinib has been approved in combination with vemurafenib in the first-line treatment for BRAF-mutated melanoma. For NRAS-mutated melanomas, MEK inhibition seems to be a therapeutic target, and association with checkpoint inhibitor provides a further therapeutic perspective. Infraclinical creatine phosphokinase (CPK) elevation is an MEK inhibitor side effect. We describe a case of focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib, 1 month after its introduction...
July 7, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28614272/quantification-of-microrna-21-and-microrna-125b-in-melanoma-tissue
#5
Anne Wandler, Rikke Riber-Hansen, Henrik Hager, Stephen J Hamilton-Dutoit, Henrik Schmidt, Boye S Nielsen, Magnus Stougaard, Torben Steiniche
Although microRNAs (miRNAs) have emerged as potent mediators of melanoma development and progression, a precise understanding of their oncogenic role remains unclear. In this study, we analysed formalin-fixed and paraffin-embedded tissues from two separate melanoma cohorts and from a series of benign melanocytic nevi. Using three different quantification methods [array analysis, quantitative PCR (qPCR) and in-situ hybridization (ISH) quantified by digital image analysis], we found considerable miRNA dysregulation in tumours...
June 13, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28609317/characteristics-of-melanoma-in-japan-a-nationwide-registry-analysis-2011-2013
#6
Taro Tomizuka, Kenjiro Namikawa, Takahiro Higashi
The distribution and incidence of melanoma vary among different races and ethnic groups. This study aimed to investigate the characteristics of cutaneous melanoma, mucosal melanoma, uveal melanoma, and melanoma of unknown primary (MUP) origin in a Japanese population. We studied these four types of melanoma in patients registered in Hospital Based Cancer Registries in Japan from 2011 to 2013. A total of 5566 patients with melanoma were identified. The distribution of sex, age, primary site, and clinical stage was analyzed...
June 12, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28604419/prognostic-significance-of-cyclooxygenase-2-and-phosphorylated-akt1-overexpression-in-primary-nonmetastatic-and-metastatic-cutaneous-melanomas
#7
Ciro D Soares, Camilla F Borges, Marcondes Sena-Filho, Oslei P de Almeida, Rafael F Stelini, Maria L Cintra, Edgard Graner, Karina G Zecchin, Jacks Jorge
Cyclooxygenase 2 (COX-2) and phosphorylated Akt1 (p-Akt1) are associated with tumor spreading, cell proliferation, high metabolism, and angiogenesis in solid tumors. This study aimed to investigate COX-2 and p-Akt1 expression in primary and metastatic melanomas by correlating with the cellular proliferation index (as revealed by minichromosome maintenance 2 expression) and the outcome of patients with malignant melanomas. Seventy-seven biopsies of malignant melanomas, including 42 primary nonmetastatic melanomas (PNMMs), 12 primary metastatic melanomas (PMMs), and 23 metastatic melanomas (MMs), were retrospectively selected...
June 9, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28574976/single-stage-excision-and-sentinel-lymph-node-biopsy-in-cutaneous-melanoma-in-selected-patients-a-retrospective-case-control-study
#8
Giuseppe Giudice, Fabio Robusto, Michelangelo Vestita, Paolo Annoscia, Rossella Elia, Eleonora Nacchiero
Sometimes, diagnostic excision of a primary melanoma would already necessitate skin grafting or transposition skin flaps, especially in areas with an esthetic or functional importance. The utility of sentinel lymph node biopsy (SLNB) after skin reconstruction is controversial. We carried out a single-institution retrospective case-control study. In patients with a wide primary lesion at high clinical-dermatoscopic suspicion for invasive melanoma in anatomical region in which a reconstruction with a skin graft or a flap is required, we proposed the performance of a confocal microscopy examination and an incisional biopsy of the primary lesion...
June 5, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28574975/a-prognostic-model-for-resectable-acral-melanoma-patients-on-the-basis-of-preoperative-inflammatory-markers
#9
Yao Wang, Xi-Zhi Wen, Hong-Jun Ba, Dan-Dan Li, Ya Ding, Ke-Feng Wang, Jing-Jing Li, Xiao-Shi Zhang
Acral melanoma is a rare disease, but is common in Asia. Knowledge of its prognostic indicators is limited. Growing evidence indicates that inflammation plays a critical role in the development and progression of acral melanoma. We developed a novel prognostic model on the basis of preoperative inflammatory markers and examined its prognostic value in a cohort of patients. This retrospective study included 232 acral melanoma patients who underwent radical surgical resection between 2000 and 2010 at the Sun Yat-sen University Cancer Center...
June 1, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28520637/clinical-experience-of-stereotactic-radiosurgery-at-a-linear-accelerator-for-intraocular-melanoma
#10
Alena Furdova, Miron Sramka, Martin Chorvath, Gabriel Kralik, Robert Furda, Michal Gregus
Long-term results with linear accelerator LINAC-based stereotactic radiosurgery for intraocular uveal malignant melanoma were assessed. A retrospective study was carried out of patients with uveal melanoma after a 1-day session stereotactic radiosurgery at LINAC in Slovakia. In the period 2001-2015, a group of 150 patients with uveal melanoma (139 choroidal melanoma, 11 ciliary body melanoma) was treated. The median tumor volume at baseline was 0.5 cm (with range from 0.2 to 1.6 cm). Tumors ranged in size from 2...
May 17, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28486243/mgmt-methylation-correlates-with-melphalan-pelvic-perfusion-survival-in-stage-iii-melanoma-patients-a-pilot-study
#11
Stefano Guadagni, Giammaria Fiorentini, Marco Clementi, Giancarlo Palumbo, Francesco Masedu, Marcello Deraco, Giovanni De Manzoni, Alessandro Chiominto, Marco Valenti, Cristina Pellegrini
Approximately 25% of melanoma patients with locoregional metastases are nonresponsive to new molecular target therapy and immunotherapy. When metastases are located in the pelvis, melphalan hypoxic perfusion can be an optional treatment. Because methylation of MGMT promoter increases the efficacy of alkylating agents, studies on melanoma outcome of patients treated with melphalan regional chemotherapy should consider this epigenetic change. This study aims to evaluate whether the survival of stage III melanoma patients treated with melphalan regional chemotherapy may be correlated with MGMT methylation status...
May 10, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28489680/cyclic-amp-epac-signaling-pathway-contributes-to-repression-of-puma-transcription-in-melanoma-cells
#12
Alexander J Lakhter, Samisubbu R Naidu
The universal second messenger cAMP regulates numerous cellular processes. Although the cAMP-signaling pathway leads to induction of gene transcription, it remains unknown whether this pathway contributes toward suppression of transcription. Here, we show that blockade of cAMP signaling using MDL12330A led to an increase in PUMA transcript levels, but not p21 in melanoma cells. cAMP downstream component Epac activation was essential for suppression of PUMA transcription as an Epac agonist reversed the effects of MDL12330A...
May 4, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28489677/futility-of-imaging-to-stage-melanoma-patients-with-a-positive-sentinel-lymph-node
#13
Lodewijka H J Holtkamp, Rebecca L Read, Louise Emmett, John F Thompson, Omgo E Nieweg
The use of staging imaging in melanoma patients with a positive sentinel lymph node (SLN) has been reported to be of limited value. Improved accuracy resulting from the development of time-of-flight positron emission tomography (PET) and ongoing image quality improvement of computed tomography (CT) may challenge this statement. Our retrospective study assessed the clinical value of routine staging CT and PET/CT imaging in a recent cohort of asymptomatic SLN-positive patients. Between January 2011 and April 2014, 143 patients with a positive SLN were routinely staged using CT of various parts of the body or whole-body PET/CT...
May 4, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28654548/histopathologic-review-of-negative-sentinel-lymph-node-biopsies-in-thin-melanomas-an-argument-for-the-routine-use-of-immunohistochemistry
#14
Anne M Stowman, Alexandra W Hickman, Alejandro A Gru, Craig L Slingluff
Sentinel lymph node biopsy (SLNB) is performed for some thin melanomas in the presence of concerning histopathological features. There are no defined standards for how sentinel nodes should be processed to detect microscopic metastases. We compared our method of serially sectioning nodes at 2-3 mm intervals and performing one hematoxylin and eosin (H&E) slide versus multiple H&E levels and utilizing immunohistochemistry (IHC). This was a retrospective review of a prospectively collected database identified patients with thin melanomas treated with wide local excision and SLNB between 1995 and 2010...
August 2017: Melanoma Research
https://www.readbyqxmd.com/read/28654547/dendritic-cell-vaccination-for-metastatic-melanoma-a-14-year-monoinstitutional-experience
#15
Francesco de Rosa, Laura Ridolfi, Laura Fiammenghi, Massimiliano Petrini, Anna M Granato, Valentina Ancarani, Elena Pancisi, Valentina Soldati, Serena Cassan, Jenny Bulgarelli, Massimo Framarini, Francesca Tauceri, Giuseppe Migliori, Claudia Brolli, Giorgia Gentili, Elisabetta Petracci, Oriana Nanni, Angela Riccobon, Ruggero Ridolfi, Massimo Guidoboni
Although immunomodulating antibodies are highly effective in metastatic melanoma, their toxicity, related to the activation of T lymphocytes, can be severe. Anticancer vaccines promote a fairly specific response and are very well tolerated, but their effectiveness has yet to be demonstrated. We have been treating patients with advanced melanoma with an autologous dendritic cell vaccine since 2001; to better characterize the safety and efficacy of our product, we designed a retrospective study on all of our patients treated with the vaccine to date...
August 2017: Melanoma Research
https://www.readbyqxmd.com/read/28654546/sex-specific-effect-of-rnasel-rs486907-and-mir-146a-rs2910164-polymorphisms-interaction-as-a-susceptibility-factor-for-melanoma-skin-cancer
#16
Antonella Sangalli, Elisa Orlandi, Albino Poli, Andrea Maurichi, Mario Santinami, Morena Nicolis, Silvia Ferronato, Giovanni Malerba, Monica Rodolfo, Macarena Gomez Lira
The genetics of melanoma is complex and, in addition to environmental influences, numerous genes are involved or contribute toward melanoma predisposition. In this study, we evaluated the possible interaction between miR-146a and one of its putative targets ribonuclease L (RNASEL) in the risk of sporadic melanoma. Polymorphisms rs2910164 in miR-146a and rs486907 in the RNASEL gene have both independently been associated with the risk of different cancers, and an interaction between them has been observed in nonmelanoma skin cancer...
August 2017: Melanoma Research
https://www.readbyqxmd.com/read/28574977/development-of-a-biclonal-cutaneous-t-cell-lymphoproliferative-process-during-treatment-with-immune-checkpoint-inhibitors-for-metastatic-melanoma
#17
Jonathan J Davick, Mark R Wick, Alejandro A Gru
The immune checkpoint inhibitors targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and the programmed death protein 1 (PD-1)/PD-L1 pathway have recently shown promising therapeutic results in patients with metastatic melanoma. Dermatologic side effects of these agents occur in ∼30-40% of cases. Here, we report the development of a biclonal cutaneous T-cell lymphoproliferative disorder in a patient being treated with ipilimumab (a CTLA-4 inhibitor) for metastatic melanoma. Nivolumab (a PD-1 inhibitor) had also been administered to him previously...
August 2017: Melanoma Research
https://www.readbyqxmd.com/read/28570389/interstitial-granulomatous-dermatitis-during-talimogen-laherparepvec-treatment
#18
Anna L Frauchiger, Marie-Charlotte Brüggen, Simone M Goldinger, Reinhard Dummer
No abstract text is available yet for this article.
August 2017: Melanoma Research
https://www.readbyqxmd.com/read/28509765/multicenter-real-life-experience-with-checkpoint-inhibitors-and-targeted-therapy-agents-in-advanced-melanoma-patients-in-switzerland
#19
Joanna Mangana, Phil F Cheng, Corina Kaufmann, Valerie C Amann, Anna L Frauchiger, Viola Stögner, Ulrike Held, Roger von Moos, Olivier Michielin, Ralph P Braun, Mitchell P Levesque, Simone M Goldinger, Reinhard Dummer
Metastatic melanoma is a highly aggressive disease. Recent progress in immunotherapy (IT) and targeted therapy (TT) has led to significant improvements in response and survival rates in metastatic melanoma patients. The current project aims to determine the benefit of the introduction of these new therapies in advanced melanoma across several regions of Switzerland. This is a retrospective multicenter analysis of 395 advanced melanoma patients treated with standard chemotherapy, checkpoint inhibitors, and kinase inhibitors from January 2008 until December 2014...
August 2017: Melanoma Research
https://www.readbyqxmd.com/read/28489679/ipilimumab-associated-cholestatic-hepatitis-a-case-report-and-literature-review
#20
Sümeyra Yildirim, Kemal Deniz, Ender Doğan, Mevlüt Başkol, Şebnem Gürsoy, Metin Özkan
Ipilimumab is a monoclonal antibody that exerts its effects by inhibiting the cytotoxic T-lymphocyte-associated protein 4 receptor on cytotoxic T lymphocytes. It is frequently used for the treatment of unresectable or metastatic melanoma. Ipilimumab may lead to several immune-related disease including colitis, thyroiditis, pneumonia, hepatitis, or pancreatitis as a side effect. Limited number of cases with hepatic damage as an ipilimumab-related adverse event has been reported in the literature. This agent has been implicated in causing acute hepatitis-like liver injury...
August 2017: Melanoma Research
journal
journal
30785
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"